The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Celiac Disease Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers.
The global Celiac Disease Drugs market size is expected to reach US$ 1603.3 million by 2029, growing at a CAGR of 14.9% from 2023 to 2029. The market is mainly driven by the significant applications of Celiac Disease Drugs in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others, are propelling Celiac Disease Drugs market. First Line of Treatment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Second Line of Treatment segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Celiac Disease Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Celiac Disease Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Celiac Disease Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Celiac Disease Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Celiac Disease Drugs covered in this report include Roche, Merck, Johnson & Johnson, BiolineRx, Pfizer, Innovate Biopharmaceuticals, ImmusanT, Novartis and Bristol-Myers Squibb, etc.
The global Celiac Disease Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Merck
Johnson & Johnson
BiolineRx
Pfizer
Innovate Biopharmaceuticals
ImmusanT
Novartis
Bristol-Myers Squibb
Immunomedics
Global Celiac Disease Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Celiac Disease Drugs market, Segment by Type:
First Line of Treatment
Second Line of Treatment
Global Celiac Disease Drugs market, by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Celiac Disease Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers.
The global Celiac Disease Drugs market size is expected to reach US$ 1603.3 million by 2029, growing at a CAGR of 14.9% from 2023 to 2029. The market is mainly driven by the significant applications of Celiac Disease Drugs in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others, are propelling Celiac Disease Drugs market. First Line of Treatment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Second Line of Treatment segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Celiac Disease Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Celiac Disease Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Celiac Disease Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Celiac Disease Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Celiac Disease Drugs covered in this report include Roche, Merck, Johnson & Johnson, BiolineRx, Pfizer, Innovate Biopharmaceuticals, ImmusanT, Novartis and Bristol-Myers Squibb, etc.
The global Celiac Disease Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Merck
Johnson & Johnson
BiolineRx
Pfizer
Innovate Biopharmaceuticals
ImmusanT
Novartis
Bristol-Myers Squibb
Immunomedics
Global Celiac Disease Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Celiac Disease Drugs market, Segment by Type:
First Line of Treatment
Second Line of Treatment
Global Celiac Disease Drugs market, by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Celiac Disease Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Celiac Disease Drugs
1.1 Celiac Disease Drugs Market Overview
1.1.1 Celiac Disease Drugs Product Scope
1.1.2 Celiac Disease Drugs Market Status and Outlook
1.2 Global Celiac Disease Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Celiac Disease Drugs Market Size by Region (2018-2029)
1.4 Global Celiac Disease Drugs Historic Market Size by Region (2018-2023)
1.5 Global Celiac Disease Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Celiac Disease Drugs Market Size (2018-2029)
1.6.1 North America Celiac Disease Drugs Market Size (2018-2029)
1.6.2 Europe Celiac Disease Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Celiac Disease Drugs Market Size (2018-2029)
1.6.4 Latin America Celiac Disease Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Celiac Disease Drugs Market Size (2018-2029)
2 Celiac Disease Drugs Market by Type
2.1 Introduction
2.1.1 First Line of Treatment
2.1.2 Second Line of Treatment
2.2 Global Celiac Disease Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Celiac Disease Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Celiac Disease Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Celiac Disease Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Celiac Disease Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Celiac Disease Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Celiac Disease Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Celiac Disease Drugs Revenue Breakdown by Type (2018-2029)
3 Celiac Disease Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacy
3.1.2 Retail Pharmacy
3.1.3 Online Pharmacy
3.1.4 Others
3.2 Global Celiac Disease Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Celiac Disease Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Celiac Disease Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Celiac Disease Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Celiac Disease Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Celiac Disease Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Celiac Disease Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Celiac Disease Drugs Revenue Breakdown by Application (2018-2029)
4 Celiac Disease Drugs Competition Analysis by Players
4.1 Global Celiac Disease Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Celiac Disease Drugs as of 2022)
4.3 Date of Key Players Enter into Celiac Disease Drugs Market
4.4 Global Top Players Celiac Disease Drugs Headquarters and Area Served
4.5 Key Players Celiac Disease Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Celiac Disease Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Celiac Disease Drugs Products, Services and Solutions
5.1.4 Roche Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Recent Developments
5.2 Merck
5.2.1 Merck Profile
5.2.2 Merck Main Business
5.2.3 Merck Celiac Disease Drugs Products, Services and Solutions
5.2.4 Merck Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Merck Recent Developments
5.3 Johnson & Johnson
5.3.1 Johnson & Johnson Profile
5.3.2 Johnson & Johnson Main Business
5.3.3 Johnson & Johnson Celiac Disease Drugs Products, Services and Solutions
5.3.4 Johnson & Johnson Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 BiolineRx Recent Developments
5.4 BiolineRx
5.4.1 BiolineRx Profile
5.4.2 BiolineRx Main Business
5.4.3 BiolineRx Celiac Disease Drugs Products, Services and Solutions
5.4.4 BiolineRx Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 BiolineRx Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Celiac Disease Drugs Products, Services and Solutions
5.5.4 Pfizer Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Innovate Biopharmaceuticals
5.6.1 Innovate Biopharmaceuticals Profile
5.6.2 Innovate Biopharmaceuticals Main Business
5.6.3 Innovate Biopharmaceuticals Celiac Disease Drugs Products, Services and Solutions
5.6.4 Innovate Biopharmaceuticals Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Innovate Biopharmaceuticals Recent Developments
5.7 ImmusanT
5.7.1 ImmusanT Profile
5.7.2 ImmusanT Main Business
5.7.3 ImmusanT Celiac Disease Drugs Products, Services and Solutions
5.7.4 ImmusanT Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 ImmusanT Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Celiac Disease Drugs Products, Services and Solutions
5.8.4 Novartis Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Bristol-Myers Squibb
5.9.1 Bristol-Myers Squibb Profile
5.9.2 Bristol-Myers Squibb Main Business
5.9.3 Bristol-Myers Squibb Celiac Disease Drugs Products, Services and Solutions
5.9.4 Bristol-Myers Squibb Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Bristol-Myers Squibb Recent Developments
5.10 Immunomedics
5.10.1 Immunomedics Profile
5.10.2 Immunomedics Main Business
5.10.3 Immunomedics Celiac Disease Drugs Products, Services and Solutions
5.10.4 Immunomedics Celiac Disease Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Immunomedics Recent Developments
6 North America
6.1 North America Celiac Disease Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Celiac Disease Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Celiac Disease Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Celiac Disease Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Celiac Disease Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Celiac Disease Drugs Market Dynamics
11.1 Celiac Disease Drugs Industry Trends
11.2 Celiac Disease Drugs Market Drivers
11.3 Celiac Disease Drugs Market Challenges
11.4 Celiac Disease Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
